Literature DB >> 18496372

Frequent intravenous pulses of growth hormone together with glutamine supplementation in prolonged critical illness after multiple trauma: effects on nitrogen balance, insulin resistance, and substrate oxidation.

Frantisek Duska1, Michal Fric, Petr Waldauf, Jaroslav Pazout, Michal Andel, Pavel Mokrejs, Petr Tůma, Jan Pachl.   

Abstract

OBJECTIVES: To estimate the efficacy and metabolic effects of growth hormone substitution as intravenous pulses together with alanyl-glutamine supplementation and tight blood glucose control in prolonged critical illness.
DESIGN: Prospective double-blind, randomized trial with open-label control arm.
SETTING: Intensive care unit of tertiary level hospital. PATIENTS: Thirty multiple trauma patients (median Injury Severity Score 34).
INTERVENTIONS: Patients were randomized, at day 4 after trauma, to receive intravenous alanyl-glutamine supplementation (0.3 g/kg x day(-1) from day 4 until day 17) and intravenous growth hormone (administered days 7-17, full dose 50 microg/kg x day(-1) from day 10 onward) (group 1, n = 10) or alanyl-glutamine and placebo (group 2, n = 10). Group 3 (n = 10) received isocaloric isonitrogenous nutrition (proteins 1.5 g/kg x day(-1)) without alanyl-glutamine.
MEASUREMENTS AND MAIN RESULTS: Cumulative nitrogen balance for the whole study period was -97 +/- 38 g of nitrogen for group 1, -193 +/- 50 g of nitrogen for group 2, and -198 +/- 77 g of nitrogen for group 3 (p < .001). This represents a daily saving of 300 g of lean body mass in group 1. Insulin-mediated glucose disposal, during euglycemic clamp, as a measure of insulin sensitivity, significantly worsened between days 4 and 17 in group 1 but improved in groups 2 and 3. Group 1 required significantly more insulin to control blood glucose, resulting in higher insulinemia (approximately 70 mIU in group 1 vs. approximately 25 mIU in groups 2 and 3). Despite this, growth hormone treatment caused an increase in plasma nonesterified fatty acid (approximately 0.5-0.6 mM in group 1 in comparison with approximately 0.2-0.3 mM in groups 2 and 3) but did not influence lipid oxidation. There were no differences in morbidity, mortality, or 6-month outcome among the groups.
CONCLUSIONS: Treatment with frequent intravenous pulses of low-dose growth hormone together with alanyl-glutamine supplementation improves nitrogen economy in patients with prolonged critical illness after multiple trauma but worsens insulin sensitivity. Tight blood glucose control is possible but requires higher doses of insulin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18496372     DOI: 10.1097/CCM.0b013e318174d499

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  9 in total

1.  Effects of growth hormone and insulin-like growth factor-1 on postoperative muscle and substrate metabolism.

Authors:  Folke Hammarqvist; Ingmar Wennström; Jan Wernerman
Journal:  J Nutr Metab       Date:  2009-11-22

2.  Lipopolysaccharide-induced failure of the gut barrier is site-specific and inhibitable by growth hormone.

Authors:  Chao Yue; Wei Wang; Wei-Liang Tian; Qian Huang; Ri-Sheng Zhao; Yun-Zhao Zhao; Qiu-Rong Li; Jie-Shou Li
Journal:  Inflamm Res       Date:  2013-01-23       Impact factor: 4.575

3.  Combined Administration of Human Ghrelin and Human Growth Hormone Attenuates Organ Injury and Improves Survival in Aged Septic Rats.

Authors:  Weng-Lang Yang; Gaifeng Ma; Mian Zhou; Monowar Aziz; Hao-Ting Yen; Spyros A Marvropoulos; Kaie Ojamaa; Ping Wang
Journal:  Mol Med       Date:  2016-01-25       Impact factor: 6.354

4.  Mitochondrial function in skeletal muscle of patients with protracted critical illness and ICU-acquired weakness.

Authors:  Kateřina Jiroutková; Adéla Krajčová; Jakub Ziak; Michal Fric; Petr Waldauf; Valér Džupa; Jan Gojda; Vlasta Němcova-Fürstová; Jan Kovář; Moustafa Elkalaf; Jan Trnka; František Duška
Journal:  Crit Care       Date:  2015-12-24       Impact factor: 9.097

Review 5.  Influence of Growth Hormone and Glutamine on Intestinal Stem Cells: A Narrative Review.

Authors:  Yun Chen; Ya-Hui Tsai; Bor-Jiun Tseng; Sheng-Hong Tseng
Journal:  Nutrients       Date:  2019-08-17       Impact factor: 5.717

6.  Functional electrical stimulation-assisted cycle ergometry in the critically ill: protocol for a randomized controlled trial.

Authors:  Petr Waldauf; Jan Gojda; Tomáš Urban; Natália Hrušková; Barbora Blahutová; Marie Hejnová; Kateřina Jiroutková; Michal Fric; Pavel Jánský; Jana Kukulová; Francis Stephens; Kamila Řasová; František Duška
Journal:  Trials       Date:  2019-12-16       Impact factor: 2.279

7.  Glutamine Supplementation in Intensive Care Patients: A Meta-Analysis of Randomized Clinical Trials.

Authors:  Massimo Oldani; Marta Sandini; Luca Nespoli; Sara Coppola; Davide Paolo Bernasconi; Luca Gianotti
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

Review 8.  Parenteral glutamine supplementation in critical illness: a systematic review.

Authors:  Paul E Wischmeyer; Rupinder Dhaliwal; Michele McCall; Thomas R Ziegler; Daren K Heyland
Journal:  Crit Care       Date:  2014-04-18       Impact factor: 9.097

Review 9.  Glutamine: an obligatory parenteral nutrition substrate in critical care therapy.

Authors:  Peter Stehle; Katharina S Kuhn
Journal:  Biomed Res Int       Date:  2015-10-01       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.